Trust Signals
Key Takeaways
- As of mid-2025, ClinicalTrials.gov listed more than 1,800 actively recruiting studies containing the term "peptide," spanning oncology, metabolic disease, infectious disease, and wound healing indications.
- GLP-1 and dual GIP/GLP-1 receptor agonist trials dominate new enrollments by volume, driven by cardiovascular and obesity outcomes data from large Phase 3 programs completed in 2023 and 2024.
- Phase designation is the single most important variable for a prospective participant: Phase 1 trials of novel peptides carry substantially higher uncertainty than Phase 3 trials of the same class where safety data already exist across thousands of patients.
- Legitimate trials never charge participants to enroll. Any "peptide clinical trial" requiring upfront fees is not a regulated study.
- ClinicalTrials.gov status labels lag real-world enrollment by weeks to months; always call the study coordinator to confirm a site is still accepting participants before traveling.
What Is the Short Answer?
Multiple peptide therapy clinical trials were actively recruiting in August 2025, spanning GLP-1 agonists, anticancer peptide conjugates, antimicrobial peptides, and wound-healing compounds. Finding one requires searching ClinicalTrials.gov by condition and ZIP code, confirming "Recruiting" status by phone, and verifying the trial holds a current IRB approval and an NCT registration number.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Trust Signals
- Key Takeaways
- Short Answer
- Which Peptide Classes Were Enrolling in August 2025?
- How to Search ClinicalTrials.gov Correctly
- Evidence Ledger: How Strong Is the Science Behind Active Peptide Trial Categories?
- What Most Pages Get Wrong About Peptide Trial Eligibility
- Mechanism with Numbers: Why Peptides Reach Trials in the First Place
- Honest Head-to-Head: Peptide Therapy Trials vs. Small-Molecule Drug Trials
- Operational Guide: How to Read a Trial Listing and Consent Document
- Chemistry of the Rules: Why Trial Peptides Are Not the Same as Compounded Clinic Peptides
- FAQ
- Sources
- Footer Disclaimers
Which Peptide Classes Were Enrolling in August 2025?
The August 2025 enrollment landscape, based on ClinicalTrials.gov registry data available through that period, showed concentration in several categories.
Incretin-class peptides (GLP-1, GIP/GLP-1 dual agonists). The largest trial volume involved compounds building on the semaglutide and tirzepatide frameworks: longer-acting formulations, oral delivery variants, and combination regimens. Outcomes trials measuring major adverse cardiovascular events (MACE) and kidney disease progression were running across hundreds of sites globally, with U.S. sites enrolling locally.
Anticancer peptide-drug conjugates. Several Phase 1 and Phase 2 trials of peptide-receptor radionuclide therapy (PRRT) and peptide-drug conjugates targeting solid tumors were open. Somatostatin-analogue-based PRRT trials for neuroendocrine tumors had multiple enrolling Phase 2/3 arms at academic cancer centers.
Antimicrobial peptides (AMPs). A smaller but growing cluster of trials studied synthetic AMPs for drug-resistant infections, mostly in Phase 1 and early Phase 2, with endpoints on pharmacokinetics and microbiological response rather than clinical cure at this stage.
Peptide vaccines and immune modulators. Cancer neoantigen peptide vaccines and peptide-based allergen immunotherapy trials were recruiting at allergy and oncology centers. Most neoantigen vaccine trials required tumor biopsy and genomic sequencing as part of screening.
Wound healing and tissue repair peptides. A smaller set of Phase 2 trials examined synthetic peptide fragments derived from growth factors for diabetic foot ulcers and surgical wound closure, primarily at wound care centers affiliated with academic hospitals.
How to Search ClinicalTrials.gov Correctly
The registry at ClinicalTrials.gov is the authoritative source for all FDA-regulated U.S. trials and many international ones. Here is the precise search path that avoids common errors.
- Go to clinicaltrials.gov and use the Advanced Search option.
- In the "Condition or disease" field, enter your specific condition (e.g., "type 2 diabetes" or "neuroendocrine tumor"), not just "peptide."
- In "Other terms," add the peptide class or name if you know it.
- Under "Status," select "Recruiting" only. "Active, not recruiting" means enrollment is closed.
- Under "Dates," filter by estimated study start or primary completion to include your target month.
- Use the "Distance" filter with your ZIP code to identify local sites.
- Call the listed Study Coordinator phone number. Do not rely solely on the online status, which can be weeks out of date.
Evidence Ledger: How Strong Is the Science Behind Active Peptide Trial Categories?
| Peptide Category | Best Available Evidence Type | Effect Direction | Confidence (for primary indication) | Key Caveat |
|---|---|---|---|---|
| GLP-1 receptor agonists (metabolic/CV) | Multiple large Phase 3 RCTs (SELECT, LEADER, SUSTAIN-6, SURPASS-CVOT) | Weight reduction, HbA1c lowering, MACE reduction confirmed | High | Trials of novel formulations or new indications do not inherit this confidence |
| Somatostatin analogue PRRT (neuroendocrine tumors) | Phase 3 RCT (NETTER-1, Strosberg et al., NEJM 2017) | Progression-free survival benefit confirmed in midgut NETs | High (for approved indication), Moderate (for extension to other NET subtypes) | Efficacy in non-midgut NETs extrapolated; ongoing trials testing this |
| Anticancer peptide-drug conjugates (novel targets) | Phase 1 and early Phase 2 human trials | Signal of activity in some tumor types; dose-limiting toxicity data emerging | Low to Moderate | Most have not reached powered Phase 3 comparison |
| Antimicrobial peptides | Phase 1 pharmacokinetic studies, preclinical MIC data | Pharmacokinetic feasibility shown; clinical efficacy unproven in humans at scale | Very Low (for clinical cure endpoints) | In vitro MIC data frequently does not translate to clinical outcomes |
| Cancer neoantigen peptide vaccines | Phase 1/2 immunogenicity and early survival data (multiple institutions) | Immune response induction confirmed; survival benefit preliminary | Low to Moderate | Highly individualized; no large RCT efficacy data yet |
| Wound-healing growth factor peptides | Phase 2 RCTs with mixed results, some positive signals | Modest acceleration of wound closure in some diabetic ulcer trials | Low to Moderate | Effect sizes small; regulatory approval not yet achieved for most compounds |
What Most Pages Get Wrong About Peptide Trial Eligibility
Most content about peptide clinical trials lists broad eligibility categories without addressing the practical barriers that disqualify most interested applicants. Here is what is routinely omitted.
Washout periods disqualify more people than diagnosis does. If you are taking a GLP-1 agonist, most incretin-class trials require a washout period, often 4 to 12 weeks, before baseline measurements are valid. Patients who have been on semaglutide for months cannot simply switch into a trial next week.
BMI floors and ceilings are strict. Metabolic trials often require a BMI in a defined range. A candidate at BMI 42 may be excluded from a trial targeting BMI 27 to 40. These cutoffs are protocol-defined and not negotiable.
Renal and hepatic function thresholds eliminate many patients. Peptides are commonly cleared renally or metabolized hepatically. Trials protect against confounded PK data by excluding participants with eGFR below a set threshold (often 45 or 60 mL/min/1.73m2) or elevated liver enzymes.
Geographic restriction to the enrolling site. A trial may appear local but have only one active site in your state. The travel burden for frequent study visits (some require monthly or biweekly visits) is substantial and is almost never discussed in marketing content about trials.
Screening failure rates are high. Industry data suggest that for every participant who enrolls in a Phase 2 metabolic trial, roughly two to four complete full screening and are excluded. Budget time for this possibility.
Mechanism with Numbers: Why Peptides Reach Trials in the First Place
Understanding why a peptide advances to human trials helps you evaluate which trials are closer to generating real clinical evidence.
Peptides achieve pharmacological specificity because their structures confer selective binding to target receptors. GLP-1 receptor agonists, for example, bind the GLP-1 receptor (GLP1R), a class B G-protein-coupled receptor, with high affinity, triggering cAMP-mediated insulin secretion in a glucose-dependent manner. This glucose dependency is the mechanistic basis for the low hypoglycemia risk that differentiates this class from sulfonylureas, and it was the rationale for advancing multiple compounds into large cardiovascular outcomes trials.
Somatostatin analogues used in PRRT bind somatostatin receptor subtype 2 (SSTR2), which is overexpressed on neuroendocrine tumor cells. The NETTER-1 trial (Strosberg et al., New England Journal of Medicine, 2017, n=229) demonstrated that lutetium-177-DOTATATE prolonged progression-free survival compared to high-dose octreotide in midgut NETs. That mechanistic specificity, receptor overexpression on tumor cells combined with radionuclide delivery, is what justified Phase 3 investment.
For novel peptide compounds entering Phase 1 in 2025, the preclinical package typically includes in vitro receptor binding assays (Ki values), rodent pharmacokinetic parameters (half-life, volume of distribution, clearance), and toxicology studies in at least two species per FDA guidance. That preclinical package does not prove human efficacy. It establishes enough plausibility and estimated safe starting dose to ethically begin human exposure. Phase 1 is safety and dose-finding, not proof of benefit.
Honest Head-to-Head: Peptide Therapy Trials vs. Small-Molecule Drug Trials
| Factor | Peptide Therapy Trials | Small-Molecule Drug Trials | Who Wins |
|---|---|---|---|
| Selectivity for target | Generally high; peptide structure confers specificity | Variable; off-target binding is common challenge | Peptides, usually |
| Oral bioavailability | Poor for most; proteolytic degradation in GI tract limits absorption | Often good; designed for oral stability | Small molecules |
| Manufacturing complexity | High; solid-phase peptide synthesis or recombinant production, cold-chain storage often required | Lower for most; standard organic synthesis | Small molecules |
| Immunogenicity risk | Present, especially for larger or modified peptides; anti-drug antibodies can neutralize effect | Lower for most small molecules | Small molecules |
| Half-life and dosing frequency | Highly variable; some engineered for once-weekly dosing (semaglutide t1/2 approximately 1 week) | Variable; many require daily dosing | Depends on compound |
| Regulatory track record for approval | Growing; GLP-1 class, PRRT agents approved; most novel peptides still pre-approval | Larger historical approval database | Small molecules overall, though peptide class catching up fast |
| Volume of active trials in 2025 | Rapidly growing; over 1,800 recruiting peptide trials on ClinicalTrials.gov mid-2025 | Larger absolute number | Small molecules by volume, peptides by growth rate |
Operational Guide: How to Read a Trial Listing and Consent Document
A ClinicalTrials.gov record contains standardized fields. Here is what each critical field tells you and what questions to ask.
NCT Number. The unique trial identifier. Search this on PubMed to find any publications from earlier phases of the same program, which reveals the compound's existing safety and efficacy record.
Sponsor vs. Collaborator. If the sponsor is an early-stage biotech with no prior approved drug, this is a higher-risk enrollment from an organizational continuity standpoint. Trials can terminate early if sponsors run out of funding.
Phase. As described above, Phase 1 equals dose-finding and safety. Phase 2 equals early efficacy signal. Phase 3 equals pivotal. Phase 4 equals post-approval surveillance. Know which you are joining.
Primary Outcome Measure and Time Frame. This tells you what the trial is actually powered to detect and how long you will be involved at minimum. A primary outcome of "change in body weight at 52 weeks" means you will be in the trial for at least a year.
Eligibility Criteria section. Read every exclusion criterion before contacting the site. This saves you and the coordinator time.
In the Informed Consent Document (ICD), look for:
- What study-related costs are covered vs. what your insurance is expected to cover.
- Whether placebo assignment is possible and what happens at trial end (do you get access to the drug?).
- The stopping rules: under what circumstances will you be removed from the study.
- Contact information for the IRB, separate from the sponsor, so you can ask independent questions.
Chemistry of the Rules: Why Trial Peptides Are Not the Same as Compounded Clinic Peptides
This distinction matters and most pages either ignore it or blur it.
Peptides are chains of amino acids linked by peptide bonds. In solution, they are subject to hydrolysis (peptide bond cleavage by water, accelerated by heat and extremes of pH), oxidation (particularly at methionine and cysteine residues), deamidation (asparagine and glutamine residues converting to aspartate and glutamate, shifting charge and potentially altering receptor binding), and aggregation (intermolecular association that reduces bioavailability and can be immunogenic).
An investigational new drug (IND) application for a peptide therapy requires the sponsor to characterize the compound's degradation pathways and demonstrate that the manufactured batch used in the trial meets defined identity, purity, and potency specifications. The batch used in your dose is traceable to a Certificate of Analysis that the FDA can audit.
A compounded peptide from a 503A or 503B pharmacy is not required to meet the same characterization standard. FDA warning letters to compounding facilities in 2023 and 2024 have documented failures including subpotent product, incorrect peptide sequence (confirmed by mass spectrometry), and sterility failures. This does not mean all compounded peptides are impure, but it means the quality assurance infrastructure that protects a trial participant does not apply to a clinic patient receiving a compounded version of the same molecule.
If you are comparing whether to join a trial or purchase a peptide from a clinic, the trial provides a characterized, auditable compound. The clinic product may or may not.
FAQ
How do I find a peptide therapy clinical trial enrolling in August 2025 near me?
Search ClinicalTrials.gov using the term "peptide" plus your condition, filter by status "Recruiting" and set the start date window to include August 2025. Enter your ZIP code under "Distance" to surface local sites. Confirm enrollment status by calling the listed study coordinator directly, as online records can lag several weeks.
What peptide classes are most commonly studied in 2025 clinical trials?
GLP-1 receptor agonists, GIP/GLP-1 dual agonists, antimicrobial peptides, anticancer peptide-drug conjugates, and peptide vaccines are the most active categories in 2025 trial registries. Incretin-based peptides dominate by trial volume due to cardiometabolic demand.
Are peptide therapy clinical trials safe to join?
All FDA-regulated trials must pass IRB review and follow 21 CFR Part 50 informed-consent rules. Safety monitoring boards review interim data on larger trials. Risk depends heavily on the peptide class, phase, and your individual health profile. Phase 1 trials carry higher uncertainty than Phase 3 trials of the same compound.
Do participants get paid for peptide clinical trials?
Compensation varies. Phase 1 healthy-volunteer studies often pay for time and travel, sometimes several hundred to a few thousand dollars total. Disease-specific trials usually offer reimbursement for expenses rather than significant pay. Payment details appear in each trial's informed-consent document and on the ClinicalTrials.gov listing.
What is the difference between a Phase 1, Phase 2, and Phase 3 peptide trial?
Phase 1 tests safety and dose range in a small group, typically 20 to 80 participants. Phase 2 tests efficacy signals and side-effect profile in a larger group, often 100 to 300. Phase 3 confirms efficacy against a control in hundreds to thousands of participants and is the basis for FDA approval. Phase 3 evidence is what regulators and clinicians weigh most heavily.
Can I join a peptide therapy trial if I am already taking a GLP-1 medication?
Most trials studying incretin-class peptides will exclude participants already on GLP-1 or GIP agonists to avoid confounding results. Trials studying a different peptide class may have no such restriction. Check each trial's specific exclusion criteria on ClinicalTrials.gov or ask the study coordinator.
How long do peptide therapy clinical trials typically last?
Duration ranges from days for single-dose pharmacokinetic studies to several years for cardiovascular outcomes trials. A typical Phase 2 metabolic peptide trial runs 12 to 52 weeks of treatment with additional follow-up visits. Confirm the commitment before signing consent.
What endpoints do most peptide therapy trials measure?
Primary endpoints depend on indication. Metabolic trials commonly use body weight change, HbA1c, or fasting glucose. Oncology peptide trials may use progression-free survival or objective response rate. Inflammatory disease trials often track validated symptom scores or biomarkers like CRP or IL-6. Mechanistic Phase 1 studies may measure pharmacokinetics, receptor occupancy, or bioavailability.
What does it mean when a trial is listed as "Active, not recruiting" versus "Recruiting"?
"Recruiting" means the trial is actively seeking new participants. "Active, not recruiting" means enrollment is complete and the trial is still running but no new participants are being accepted. For August 2025 enrollment, you need trials with "Recruiting" status and an estimated primary completion date after August 2025.
Are compounded peptides used in clinical trials the same as what medspas sell?
No. Clinical trial investigational peptides are manufactured under strict GMP conditions, tested for identity, purity, and potency by the sponsor, and the batch is linked to a specific protocol. Compounded peptides sold at medspas are not FDA-approved drugs and are subject to far less rigorous quality oversight. Purity and dose accuracy are not guaranteed.
How do I verify a peptide clinical trial is legitimate before enrolling?
Confirm the trial has an NCT number registered on ClinicalTrials.gov. Verify the sponsor is a recognized institution, pharmaceutical company, or NIH entity. Ask for the IRB approval letter and the informed-consent document before any procedures or payments. Legitimate trials never charge participants to enroll.
Will participating in a peptide trial affect my insurance or future coverage?
Under the ACA, health insurers cannot deny coverage solely because you participated in an approved clinical trial. However, some insurers may scrutinize claims related to experimental treatments. Discuss with your insurer and review the trial's coverage policy before enrolling. Trials often cover costs of the investigational drug and study-related procedures directly.
Sources
- ClinicalTrials.gov. U.S. National Library of Medicine. Registry and results database. clinicaltrials.gov (accessed May 2026, reflecting August 2025 data).
- Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1). New England Journal of Medicine. 2017;376(2):125-135.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232.
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). New England Journal of Medicine. 2016;375(4):311-322.
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016;375(19):1834-1844.
- U.S. Food and Drug Administration. 21 CFR Part 50: Protection of Human Subjects. U.S. Government Publishing Office.
- U.S. Food and Drug Administration. Guidance for Industry: IND Applications for Clinical Investigations: Regulatory and Administrative Recommendations. FDA, 2023.
- U.S. Food and Drug Administration. Warning letters to compounding facilities, 2023-2024. FDA.gov/inspections-compliance-enforcement-and-criminal-investigations.
- Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. Drug Discovery Today. 2013;18(17-18):807-817.
- Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. 2015;20(1):122-128.
- Patient Protection and Affordable Care Act, Section 2709 (Clinical Trial Coverage). 42 U.S.C. 300gg-8.
Footer Disclaimers
Platform: FormBlends is an informational platform. This page does not constitute medical advice, does not create a physician-patient relationship, and should not be used as a substitute for consultation with a qualified healthcare provider.
Research Compound Notice: Some peptides discussed on this page are investigational compounds not approved by the FDA for any indication. Information about these compounds is provided for educational purposes regarding the clinical trial process only.
Results Disclaimer: Outcomes described from cited clinical trials apply to the specific populations studied under controlled conditions. Individual results vary. Enrollment in any clinical trial does not guarantee benefit.
Trademark Notice: Product and drug names referenced on this page (including semaglutide, tirzepatide, lutetium-177-DOTATATE) are trademarks of their respective owners. FormBlends has no affiliation with any pharmaceutical manufacturer or clinical trial sponsor mentioned herein.